GT Biopharma is filing for an IPO. The clinical-stage immuno-oncology company is developing TriKE, a platform that engineers a patient's own NK cells to hunt and kill cancer cells. Zero revenue, persi

The financial picture is rough: no revenue, mounting losses since inception, and a stock down ~78% over the past year. Nasdaq already flagged an equity shortfall with a January 2025 compliance deadline. This is a company that needs the public markets more than the public marke... Biggest risk in this filing: the pipeline is early. Lead candidates GTB-3650 and GTB-5550 are both in Phase 1, and the company admits its product candidates may never win regulatory approval. Add in the explicit warning that it will need substantial additional capital to keep ... Use of proceeds will matter here — the company raised $5.45M via private placement in May 2025 and secured up to $20M in additional equity funding. Investors should watch how much of this IPO is funding R&D versus just keeping the lights on. Bottom line: early-stage science, a beaten-down share price, and a biotech IPO window that just posted a 10-year low. GT Biopharma is a binary bet on NK cell engagers. Size positions accordingly.

The financial picture is rough: no revenue, mounting losses since inception, and a stock down ~78% over the past year. Nasdaq already flagged an equity shortfall with a January 2025 compliance deadlin